William Blair reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Thursday morning, AnalystRatings.com reports.

Other analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a buy rating on shares of Crispr Therapeutics in a report on Thursday, January 30th. Needham & Company LLC reaffirmed a buy rating and issued a $84.00 price target on shares of Crispr Therapeutics in a report on Monday, December 23rd. Oppenheimer boosted their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research note on Monday, November 25th. BidaskClub downgraded shares of Crispr Therapeutics from a sell rating to a strong sell rating in a report on Tuesday. Finally, TheStreet raised shares of Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $78.29.

Shares of NASDAQ CRSP traded down $2.32 during trading on Thursday, reaching $55.80. 1,623,146 shares of the stock were exchanged, compared to its average volume of 1,113,728. The business’s 50-day moving average price is $57.85 and its 200 day moving average price is $53.01. Crispr Therapeutics has a twelve month low of $30.75 and a twelve month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of -121.30 and a beta of 3.25.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $1.19. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $77.00 million for the quarter, compared to analysts’ expectations of $39.08 million. During the same period in the previous year, the company posted ($0.92) earnings per share. The business’s revenue for the quarter was up 76900.0% compared to the same quarter last year. As a group, sell-side analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. 21.40% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. NEXT Financial Group Inc grew its stake in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the period. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics in the third quarter worth approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $26,000. Webster Bank N. A. bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $26,000. Finally, Advisory Services Network LLC boosted its holdings in Crispr Therapeutics by 146.0% in the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock worth $41,000 after acquiring an additional 400 shares in the last quarter. 50.01% of the stock is owned by institutional investors and hedge funds.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Guidelines for Successful Channel Trading

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.